Serum soluble E-selectin and NT-proBNP levels additively predict mortality in diabetic patients with chronic heart failure

Judit Czúcz, L. Cervenák, Zsolt Förhécz, Tímea Gombos, Zoltán Pozsonyi, Jan Kunde, I. Karádi, Lívia Jánoskuti, Z. Prohászka

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background Neuroendocrine activation with endothelial dysfunction is a key pathophysiological process in chronic heart failure (CHF). Although increased soluble E-selectin (sE-selectin) levels predict adverse events in several forms of cardiovascular disease, there are only scarce data on its predictive value in CHF. The aim of our study was to investigate whether sE-selectin is a useful predictor of mortality in CHF patients and whether its predictive power is additive to that of NT-proBNP. Methods Plasma levels of sE-selectin were measured by ELISA in 192 CHF patients with clinical systolic heart failure. The study population was followed up for 14.9 months on average; 46 patients died during this period. Results Levels of sE-selectin were significantly higher in non-surviving patients than in survivors (p = 0.005) and significantly correlated with the following inflammatory markers: CRP (r = 0.242, p = 0.001), TNF-a (r = 0.201, p = 0.005), TNF-RII (r = 0.207, p = 0.004), and IL-6 (r = 0.339, p\0.0001). According to Cox regression analysis of the prediction power of sE-selectin for all-cause mortality, high sE-selectin levels independently and significantly predicted short-term mortality in CHF (HR 1.47, 95% CI 1.103-1.956). Furthermore, sE-selectin predicted mortality in CHF patients with concomitant diabetes mellitus, as well as simultaneously elevated sE-selectin and NT-proBNP levels additively predicted mortality. Conclusions This study demonstrated a weak correlation of sE-selectin level with inflammatory markers and prediction of short-term mortality in diabetic CHF patients. Elevated serum sE-selectin levels and concomitantly increased NT-proBNP concentrations have additive predictive power in CHF. This suggests that parallel activation of various pathophysiological pathways confers increased risk of adverse outcome in CHF.

Original languageEnglish
Pages (from-to)587-594
Number of pages8
JournalClinical Research in Cardiology
Volume100
Issue number7
DOIs
Publication statusPublished - Jul 2011

Fingerprint

E-Selectin
Heart Failure
Mortality
Serum
pro-brain natriuretic peptide (1-76)
Receptors, Tumor Necrosis Factor, Type II
Systolic Heart Failure
Survivors
Interleukin-6
Diabetes Mellitus
Cardiovascular Diseases
Enzyme-Linked Immunosorbent Assay
Regression Analysis

Keywords

  • Heart failure
  • Inflammation
  • NT-proBNP
  • SE-selectin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Serum soluble E-selectin and NT-proBNP levels additively predict mortality in diabetic patients with chronic heart failure. / Czúcz, Judit; Cervenák, L.; Förhécz, Zsolt; Gombos, Tímea; Pozsonyi, Zoltán; Kunde, Jan; Karádi, I.; Jánoskuti, Lívia; Prohászka, Z.

In: Clinical Research in Cardiology, Vol. 100, No. 7, 07.2011, p. 587-594.

Research output: Contribution to journalArticle

Czúcz, Judit ; Cervenák, L. ; Förhécz, Zsolt ; Gombos, Tímea ; Pozsonyi, Zoltán ; Kunde, Jan ; Karádi, I. ; Jánoskuti, Lívia ; Prohászka, Z. / Serum soluble E-selectin and NT-proBNP levels additively predict mortality in diabetic patients with chronic heart failure. In: Clinical Research in Cardiology. 2011 ; Vol. 100, No. 7. pp. 587-594.
@article{b775615197914560ac5db1891b97913c,
title = "Serum soluble E-selectin and NT-proBNP levels additively predict mortality in diabetic patients with chronic heart failure",
abstract = "Background Neuroendocrine activation with endothelial dysfunction is a key pathophysiological process in chronic heart failure (CHF). Although increased soluble E-selectin (sE-selectin) levels predict adverse events in several forms of cardiovascular disease, there are only scarce data on its predictive value in CHF. The aim of our study was to investigate whether sE-selectin is a useful predictor of mortality in CHF patients and whether its predictive power is additive to that of NT-proBNP. Methods Plasma levels of sE-selectin were measured by ELISA in 192 CHF patients with clinical systolic heart failure. The study population was followed up for 14.9 months on average; 46 patients died during this period. Results Levels of sE-selectin were significantly higher in non-surviving patients than in survivors (p = 0.005) and significantly correlated with the following inflammatory markers: CRP (r = 0.242, p = 0.001), TNF-a (r = 0.201, p = 0.005), TNF-RII (r = 0.207, p = 0.004), and IL-6 (r = 0.339, p\0.0001). According to Cox regression analysis of the prediction power of sE-selectin for all-cause mortality, high sE-selectin levels independently and significantly predicted short-term mortality in CHF (HR 1.47, 95{\%} CI 1.103-1.956). Furthermore, sE-selectin predicted mortality in CHF patients with concomitant diabetes mellitus, as well as simultaneously elevated sE-selectin and NT-proBNP levels additively predicted mortality. Conclusions This study demonstrated a weak correlation of sE-selectin level with inflammatory markers and prediction of short-term mortality in diabetic CHF patients. Elevated serum sE-selectin levels and concomitantly increased NT-proBNP concentrations have additive predictive power in CHF. This suggests that parallel activation of various pathophysiological pathways confers increased risk of adverse outcome in CHF.",
keywords = "Heart failure, Inflammation, NT-proBNP, SE-selectin",
author = "Judit Cz{\'u}cz and L. Cerven{\'a}k and Zsolt F{\"o}rh{\'e}cz and T{\'i}mea Gombos and Zolt{\'a}n Pozsonyi and Jan Kunde and I. Kar{\'a}di and L{\'i}via J{\'a}noskuti and Z. Proh{\'a}szka",
year = "2011",
month = "7",
doi = "10.1007/s00392-011-0283-6",
language = "English",
volume = "100",
pages = "587--594",
journal = "Clinical Research in Cardiology",
issn = "1861-0684",
publisher = "D. Steinkopff-Verlag",
number = "7",

}

TY - JOUR

T1 - Serum soluble E-selectin and NT-proBNP levels additively predict mortality in diabetic patients with chronic heart failure

AU - Czúcz, Judit

AU - Cervenák, L.

AU - Förhécz, Zsolt

AU - Gombos, Tímea

AU - Pozsonyi, Zoltán

AU - Kunde, Jan

AU - Karádi, I.

AU - Jánoskuti, Lívia

AU - Prohászka, Z.

PY - 2011/7

Y1 - 2011/7

N2 - Background Neuroendocrine activation with endothelial dysfunction is a key pathophysiological process in chronic heart failure (CHF). Although increased soluble E-selectin (sE-selectin) levels predict adverse events in several forms of cardiovascular disease, there are only scarce data on its predictive value in CHF. The aim of our study was to investigate whether sE-selectin is a useful predictor of mortality in CHF patients and whether its predictive power is additive to that of NT-proBNP. Methods Plasma levels of sE-selectin were measured by ELISA in 192 CHF patients with clinical systolic heart failure. The study population was followed up for 14.9 months on average; 46 patients died during this period. Results Levels of sE-selectin were significantly higher in non-surviving patients than in survivors (p = 0.005) and significantly correlated with the following inflammatory markers: CRP (r = 0.242, p = 0.001), TNF-a (r = 0.201, p = 0.005), TNF-RII (r = 0.207, p = 0.004), and IL-6 (r = 0.339, p\0.0001). According to Cox regression analysis of the prediction power of sE-selectin for all-cause mortality, high sE-selectin levels independently and significantly predicted short-term mortality in CHF (HR 1.47, 95% CI 1.103-1.956). Furthermore, sE-selectin predicted mortality in CHF patients with concomitant diabetes mellitus, as well as simultaneously elevated sE-selectin and NT-proBNP levels additively predicted mortality. Conclusions This study demonstrated a weak correlation of sE-selectin level with inflammatory markers and prediction of short-term mortality in diabetic CHF patients. Elevated serum sE-selectin levels and concomitantly increased NT-proBNP concentrations have additive predictive power in CHF. This suggests that parallel activation of various pathophysiological pathways confers increased risk of adverse outcome in CHF.

AB - Background Neuroendocrine activation with endothelial dysfunction is a key pathophysiological process in chronic heart failure (CHF). Although increased soluble E-selectin (sE-selectin) levels predict adverse events in several forms of cardiovascular disease, there are only scarce data on its predictive value in CHF. The aim of our study was to investigate whether sE-selectin is a useful predictor of mortality in CHF patients and whether its predictive power is additive to that of NT-proBNP. Methods Plasma levels of sE-selectin were measured by ELISA in 192 CHF patients with clinical systolic heart failure. The study population was followed up for 14.9 months on average; 46 patients died during this period. Results Levels of sE-selectin were significantly higher in non-surviving patients than in survivors (p = 0.005) and significantly correlated with the following inflammatory markers: CRP (r = 0.242, p = 0.001), TNF-a (r = 0.201, p = 0.005), TNF-RII (r = 0.207, p = 0.004), and IL-6 (r = 0.339, p\0.0001). According to Cox regression analysis of the prediction power of sE-selectin for all-cause mortality, high sE-selectin levels independently and significantly predicted short-term mortality in CHF (HR 1.47, 95% CI 1.103-1.956). Furthermore, sE-selectin predicted mortality in CHF patients with concomitant diabetes mellitus, as well as simultaneously elevated sE-selectin and NT-proBNP levels additively predicted mortality. Conclusions This study demonstrated a weak correlation of sE-selectin level with inflammatory markers and prediction of short-term mortality in diabetic CHF patients. Elevated serum sE-selectin levels and concomitantly increased NT-proBNP concentrations have additive predictive power in CHF. This suggests that parallel activation of various pathophysiological pathways confers increased risk of adverse outcome in CHF.

KW - Heart failure

KW - Inflammation

KW - NT-proBNP

KW - SE-selectin

UR - http://www.scopus.com/inward/record.url?scp=80051803006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051803006&partnerID=8YFLogxK

U2 - 10.1007/s00392-011-0283-6

DO - 10.1007/s00392-011-0283-6

M3 - Article

VL - 100

SP - 587

EP - 594

JO - Clinical Research in Cardiology

JF - Clinical Research in Cardiology

SN - 1861-0684

IS - 7

ER -